Mishelle Estefania Garces Lopez

Mishelle Estefania Garces Lopez

Auto-generated profile, based on publicly available information

Mishelle Estefania Garces Lopez

EMI FALCK, Medical Department, Quito, Ecuador

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2024 in International Journal of Medical Science and Dental Health
Verified
Journal Article
Closed access
BPBolívar Leonardo Saquinga Pujos
Bolívar Leonardo Saquinga Pujos
SHSantiago Israel Cárdenas Herrera
Santiago Israel Cárdenas Herrera
DJDaniela Geomar Salazar Jara
Daniela Geomar Salazar Jara
ATAndrés Geovanny Puchi Timbe
Andrés Geovanny Puchi Timbe
JDJean Pierre Villafuerte Demera
Jean Pierre Villafuerte Demera
MLMishelle Estefania Garcés López
Mishelle Estefania Garcés López

1 August 2025 in Salud, Ciencia y Tecnología
Verified
Journal Article
Open access
PDF file
MCMelina Carlos
Melina Carlos
MAMitchell Walter Carbajal Alvarado
Mitchell Walter Carbajal Alvarado
CDCesar Augusto Flores Duenas
Cesar Augusto Flores Duenas
NSNatalia Quintero Serrano
Natalia Quintero Serrano
LOLuisa Alejandra Penagos Ochoa
Luisa Alejandra Penagos Ochoa
MLMishelle Estefania Garces Lopez
Mishelle Estefania Garces Lopez
Introduction: Extracorporeal membrane oxygenation (ECMO) is an advanced life support for critically ill patients with refractory cardiogenic shock. However, evidence on its impact on mortality, hemodynamic recovery, and complications remains heterogeneous. This review aims to systematically evaluate ECMO’s impact on mortality and hemodynamic recovery in adult patients with refractory cardiogenic shock, addressing gaps and variations in existing literature.Material and Methods: This systematic review followed PRISMA guidelines. Databases searched were PubMed, Cochrane Library, and Google Scholar. Two reviewers independently selected studies, extracted data, and assessed quality using the Newcastle–Ottawa Scale. Findings were synthesized narratively due to study heterogeneity.Results: Mortality rates ranged widely from 33 to 75%, reflecting differences in patient populations and timing of ECMO initiation. Early ECMO initiation within less than one hour of shock onset was associated with a 47 percent reduction in mortality risk. In-hospital mortality was approximately 40%, increasing to nearly 60% at one-year follow-up. Success rates for weaning patients off ECMO varied between 53% and 88%. Hemodynamic improvements following ECMO support included increased blood pressure, improved left ventricular ejection fraction, and decreased serum lactate levels. Complications were frequent and diverse, predominantly bleeding, stroke, renal failure, and limb ischemia. Bleeding complications are strongly correlated with mortality.Conclusions: ECMO provides crucial circulatory support in refractory cardiogenic shock, improving hemodynamic parameters but with persistently high mortality and complication rates. Early initiation and careful patient selection are vital for optimizing outcomes, underscoring the need for multidisciplinary management and further high-quality prospective studies.